2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

4994 Uncovering mechanisms connecting inflammatory signaling to KMT2A fusion protein programs

Perpetual Serwaah Kyei, MS, Therese Vu, PhD2, Wenjuan Liao, PhD3, Akihiko Yokoyama, phd4, Tzu Phang5, Julian Grandvallet Contreras6, John Duy Pham, BS7, Yufei Chen, PhD8, Weiwei Yang, PhD9, Daniel Starczynowski, PhD10, Ashley Cochran, PhD11, Patricia Ernst, PhD12
1 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
2 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
3 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
4 Tsuruoka Metabolomics Laboratory, National Cancer Center, Tsuruoka, Japan
5 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
6 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
7 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States
8 PFIZER, SEATTLE, Washington, United States
9 New England Biolabs Inc, IPSWICH, United States
10 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
11 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
12 University of Colorado Anschutz Medical Campus, AURORA, Colorado, United States

KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML), despite intensive treatment, has event-free survival rates that remain at approximately 40–50% in pediatric KMT2A-r patients. Targeting menin, an essential cofactor, has emerged as a promising therapeutic strategy. Although menin inhibitors have recently shown impressive response rates, genetic and adaptive resistance mechanisms to menin inhibitors have emerged. Identifying complementary pathways that support leukemia survival is therefore essential for developing more effective therapeutic strategies. Inflammatory signaling has been implicated in AML pathogenesis, with pediatric AML exhibiting elevated expression of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-α. Independently, multiple components of the IL-1/IRAK4/NF-κB signaling axis have been implicated in KMT2A-r leukemia, suggesting that inflammatory signaling may cooperate with KMT2A fusion-driven transcription to sustain leukemia survival.

To identify mechanisms that may cooperate with KMT2A-r pathways, we tested two hypotheses connected to inflammatory signaling. The first involved testing a model in which IL1 signaling modulates competition between wild-type (WT) KMT2A and KMT2A fusion proteins to attenuate leukemogenesis. Using genetically engineered murine and human KMT2A::MLLT3 leukemia models permitting inducible WT KMT2A overexpression or CRISPR/CAS9 mediated deletion and re-expression of endogenous KMT2A, we found that altering WT KMT2A abundance did not affect leukemia initiation, disease latency, leukemia burden, and expression of canonical KMT2A fusion target genes. Fractionation-assisted native chromatin immunoprecipitation (Fan-ChIP) studies demonstrated overlapping genomic occupancy of WT and fusion KMT2A at shared target loci; however, modulation of WT KMT2A expression neither displaced KMT2A fusion binding nor altered transcriptional output. Further, loss or overexpression of WT KMT2A did not impact sensitivity to IL1 receptor-associated kinase (IRAK) inhibitors. Together, these findings demonstrate that WT KMT2A does not regulate KMT2A-r leukemia through competitive chromatin occupancy and is unlikely to mediate the impact of pro-survival IL1 signaling. Second, we tested whether NF-κB survival signaling was a major downstream effector of IRAK4 inhibition. In KMT2A::MLLT3 cells, IRAK4 inhibition rapidly reduced phosphorylation of the NF-κB subunit p65 followed by cell death ~10 hours later. We show that activation of the NF-κB pathway through expression of constitutively active IKK beta (IKK2SE) partially rescued survival of cells undergoing IRAK4 inhibition. Genome-wide studies combining IRAK4 inhibition and IKK2SE identified two groups of deregulated genes, those dominantly suppressed by IRAK4 inhibition and those that could be dominantly re-activated by constitutive NF-κB activity. These data suggest that the impact of IRAK inhibitors in KMT2A-r AML occurs partly through suppression of inflammatory signaling, as well as inhibition of other processes such as ribosome biogenesis.

Finally, single cell CITE-seq analyses of primary KMT2A-r AML specimens (I. Shelton, A. Gillen, C. Jordan unpublished) revealed differentiation heterogeneity with varying degrees of primitive and monocytic composition. KMT2A fusion targets were highly expressed in the primitive components whereas NF-κB targets were enriched in the more monocytic component. These findings suggest that distinct leukemia cell states may rely on complementary survival pathways. To identify actionable inflammatory signaling dependencies that cooperate with KMT2A fusion-driven transcription, we initiated CRISPR-Cas9 dropout screens encompassing >300 innate immune signaling mediators connecting IL1 signaling with NF-κB activity. Collectively, our findings identify inflammatory signaling as a complementary survival program in KMT2A-r AML and provide a mechanistic rationale for combined targeting of menin driven transcription and NF-κB signaling to overcome therapeutic resistance and improve patient outcomes.

Perpetual Serwaah Kyei, MS: No relevant conflicts of interest to declare.